1. Storage of product for >8 hours is associated with a
rapid decrease in WBC function, making this a less
2. Fever, alloimmunization, TRALI, and CMV infection
have all been reported complications.
Fresh Frozen Plasma, Frozen Thawed
Clinically significant bleeding or for correction of
hemostatic defects prior to invasive procedures in the
a. Complex factor deficiency unresponsive to vitamin K
c. Support during the management of disseminated
a. Congenital or acquired dys- or hypofibrinogenemia*
b. Congenital FXIII deficiency in the absence of FXIII
c. Bleeding associated with von Willebrand disease,
hemophilia A when virally inactivated plasmaderived or recombinant factor products are unavailable.
2. Exert caution when possibility of volume overload
3. Use with caution in the setting of NEC and/or
T-activation as it may aggravate hemolysis (39).
4. Not indicated for hypovolemic shock in the absence of
1. Cross-matching is not required because type-specific or
AB-negative product is usually issued.
2. Dose of FFP is 10 to 20 mL/kg; multiple transfusions
may be required until the underlying condition
3. Once thawed, FFP should be transfused within 6 hours
for labile factor replacement.
4. In cases for which repeated FFP transfusions are
required, a thawed unit from a single donor may be
divided into smaller aliquots and used within 24 hours
if stored between 1°C and 6°C.
5. A dose of 1 U/5 kg of cryoprecipitate will increase the
total fibrinogen by approximately 100 mg/dL in the
absence of ongoing consumption.
6. 1 U of cryoprecipitate equals approximately 12 to
Directed donations provide no known benefit in terms of
increased safety and may pose unique immunologic and
serologic risks to the neonate (30,40).
*In the presence of active bleeding or planned invasive procedures.
No comments:
Post a Comment